Skip to Main Content
Anand Rohatgi, M.D.

Anand Rohatgi, M.D.

Cardiovascular Director of Academic Development

Professor

School
Medical School
Department
Internal Medicine

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Anand Rohatgi, M.D., M.S.C.S., FACC, FAHA, is a Professor of Medicine in the Department of Internal Medicine’s Division of Cardiology at UT Southwestern Medical Center. He specializes in preventive cardiology.

    Dr. Rohatgi earned his medical degree at Duke University School of Medicine. He completed an internal medicine residency at the University of Pennsylvania Health System and a cardiology fellowship at UT Southwestern. He also holds a master’s degree in clinical science from UT Southwestern.

    Board certified in cardiovascular disease and internal medicine, he joined the UT Southwestern faculty in 2008.

    In addition to his clinical roles, Dr. Rohatgi is the Associate Program Director of UTSW’s Cardiovascular Fellowship, and he serves on several campus committees to enhance clinical research. He is an active CME speaker and has given several invited national talks.

    Dr. Rohatgi’s research focuses on the role of novel biomarkers in improving risk prediction for atherosclerosis and coronary artery disease. Specifically, his main area of interest is the role of high-density lipoproteins (HDL) in cardiovascular disease. He also focuses on high-risk populations, including those with diabetes and people of South Asian ancestry.

    He is currently the principal investigator of “The Genetic and Molecular Basis of Cholesterol Efflux,” a five-year study funded by the National Institutes of Health (NIH) R01 award, and "Mentoring Patient-Oriented Research in Deep Lipid Phenotyping for Cardiovascular Disease," a five-year study funded by the NIH K24 award. He has received past awards for research from the American Heart Association.

    He also is the principal investigator of a five year study "Lipoprotein Metabolism and Excess Cardiometabolic Risk in South Asians" funded by the National Institutes of Health (NIH) R01 award (2022-2027). This grant focused on novel markers of lipids like HDL function in South Asians utilizing the MASALA cohort in the U.S. and the U.K. biobank cohort in Europe.

    Dr. Rohatgi serves as a reviewer for a number of publications, including The Lancet, Journal of the American Medical Association, Journal of the American Heart Association, American Journal of Cardiology, and Arteriosclerosis, Thrombosis, and Vascular Biology. He is an Associate Editor for Circulation and on the Editorial Board for the Journal of Clinical Lipidology.

    He is a Fellow of both the American College of Cardiology and the American Heart Association and a member of the American College of Physicians, the National Lipid Association, and the American Society of Preventive Cardiology, among other professional organizations. He also chairs the board of directors of the nonprofit Texas Loves Children.

  • Education
    Medical School
    Duke University School of Medicine (2002)
    Residency
    University of Pennsylvania Health System (2005), Internal Medicine
    Fellowship
    UT Southwestern Medical Center (2008), Cardiology
  • Research Interest
    • Biomarkers for Atherosclerosis and Coronary Artery Disease
    • High-density Lipoprotein
    • Inflammation and Atherosclerosis
  • Publications

    Star Featured Publications

    Featured Featured Featured Featured Featured Featured
    Stressing the Endothelium to Assess Localized Inflammatory Potential and the Risk for Atherosclerotic Cardiovascular Disease.
    Rohatgi A, Circulation 2021 May 143 20 1946-1948
    Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study).
    Akinmolayemi O, Saldanha S, Joshi PH, Deodhar S, Ayers CR, Neeland IJ, Rohatgi A, PLoS One 2021 16 9 e0257574
    Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk.
    Mehta A, Virani SS, Ayers CR, Sun W, Hoogeveen RC, Rohatgi A, Berry JD, Joshi PH, Ballantyne CM, Khera A, J. Am. Coll. Cardiol. 2020 Aug 76 7 781-793
    Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events.
    Riggs KA, Joshi PH, Khera A, Singh K, Akinmolayemi O, Ayers CR, Rohatgi A, J Clin Med 2019 Dec 8 12
  • Books

    Featured 

  • Honors & Awards
    • Discovery Grant Awardee
      American Heart Association Institute of Precision Medicine (2015)
    • Young Investigator Award
      American Association of Cardiologists of Indian Origin (2010)
    • Council on Arteriosclerosis, Thrombosis, and Vascular Biology Travel Award for Young Investigators
      (2008)
    • Finalist - Cardiovascular Young Investigator?s Forum
      Northwestern University (2008)
    • Outstanding Resident Teaching Award
      (2005)
  • Professional Associations/Affiliations
    • American College of Cardiology
    • American Heart Association
    • American Society of Preventive Cardiology (2019)
    • Dallas County Medical Society
    • National Lipid Association
    • Texas Medical Association